{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:20:20Z","timestamp":1771478420487,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["LE 1046\/8-1"],"award-info":[{"award-number":["LE 1046\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bmc.2023.117558","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:36:16Z","timestamp":1702388176000},"page":"117558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["\u03c9-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted glycine amides and related compounds as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1)"],"prefix":"10.1016","volume":"98","author":[{"given":"Timo","family":"P\u00f6stges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Galster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kampschulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walburga","family":"Hanekamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117558_b0005","first-page":"87","article-title":"Amine oxidases","volume":"Vol. 2","author":"Floris","year":"2013"},{"key":"10.1016\/j.bmc.2023.117558_b0010","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.jmb.2020.03.007","article-title":"Bioinformatic analysis of the flavin-dependent amine oxidase superfamily: Adaptations for substrate specificity and catalytic diversity","volume":"432","author":"Tararina","year":"2020","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2023.117558_b0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.abb.2013.12.022","article-title":"Human copper-dependent amine oxidases","volume":"546","author":"Finney","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bmc.2023.117558_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1472-8206.2001.00011.x","article-title":"Biotransformation of xenobiotics by amine oxidases","volume":"15","author":"Benedetti","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117558_b0025","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.116.071753","article-title":"Cytochrome P450 and non-cytochrome P450 oxidative metabolism: Contributions to the pharmacokinetics, safety, and efficacy of xenobiotics","volume":"44","author":"Foti","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2023.117558_b0030","doi-asserted-by":"crossref","first-page":"e01051","DOI":"10.1002\/prp2.1051","article-title":"Metabolism of sumatriptan revisited","volume":"11","author":"P\u00f6stges","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bmc.2023.117558_b0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2023.117558_b0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/BJ20090598","article-title":"Polyamine catabolism and disease","volume":"421","author":"Casero","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.bmc.2023.117558_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ympev.2019.106571","article-title":"Evolution and functional classification of mammalian copper amine oxidases","volume":"139","author":"Lopes de Carvalho","year":"2019","journal-title":"Mol Phylogenet Evol"},{"key":"10.1016\/j.bmc.2023.117558_b0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000171432","article-title":"Diamine oxidase: an overview of historical, biochemical and functional aspects","volume":"12","author":"Wolvekamp","year":"1994","journal-title":"Dig Dis"},{"key":"10.1016\/j.bmc.2023.117558_b0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/geno.1996.4570","article-title":"Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping","volume":"40","author":"Imamura","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.bmc.2023.117558_b0060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/ars.2017.7418","article-title":"Vascular adhesion protein-1: a cell surface amine oxidase in translation","volume":"30","author":"Salmi","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bmc.2023.117558_b0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.RES.0000134630.68877.2F","article-title":"Origins of serum semicarbazide-sensitive amine oxidase","volume":"95","author":"Stolen","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.bmc.2023.117558_b0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1570-9639(03)00047-5","article-title":"Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology","volume":"1647","author":"Boomsma","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmc.2023.117558_b0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(01)00151-9","article-title":"Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus","volume":"15","author":"Gr\u00f6nvall-Nordquist","year":"2001","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.bmc.2023.117558_b0080","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1096\/fj.03-0562fje","article-title":"Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications","volume":"18","author":"Stolen","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2023.117558_b0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40942-021-00288-7","article-title":"Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy","volume":"7","author":"Boyer","year":"2021","journal-title":"Int. J. Retina Vitreous."},{"key":"10.1016\/j.bmc.2023.117558_b0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s43440-021-00343-y","article-title":"Vascular adhesion protein-1 and microvascular diabetic complications","volume":"74","author":"Singh","year":"2022","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bmc.2023.117558_b0095","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1084\/jem.178.6.2255","article-title":"Induction and function of vascular adhesion protein-1 at sites of inflammation","volume":"178","author":"Salmi","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2023.117558_b0100","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.161.3.1549","article-title":"Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases","volume":"161","author":"Kurkij\u00e4rvi","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2023.117558_b0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1096\/fj.00-0240com","article-title":"Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo","volume":"15","author":"Tohka","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2023.117558_b0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cmdc.200600245","article-title":"Inhibition of VAP1: quickly gaining ground as an anti-inflammatory therapy","volume":"2","author":"Yraola","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2023.117558_b0115","series-title":"Chapter 15 Semicarbazide sensitive amine oxidase and vascular adhesion protein-1: One protein being validated as a therapeutic target for inflammatory diseases","first-page":"229","author":"McDonald","year":"2007"},{"key":"10.1016\/j.bmc.2023.117558_b0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10408363.2015.1050714","article-title":"Vascular adhesion protein-1: Role in human pathology and application as a biomarker","volume":"52","author":"Pannecoeck","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.bmc.2023.117558_b0125","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.3390\/ijms22073365","article-title":"SSAO\/VAP-1 in cerebrovascular disorders: A potential therapeutic target for stroke and Alzheimer's disease","volume":"22","author":"Unzeta","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2023.117558_b0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.2042-7158.1985.tb05075.x","article-title":"An allylamine derivative (MDL 72145) with potent irreversible inhibitory actions on rat aorta semicarbazide-sensitive amine oxidase","volume":"37","author":"Lyles","year":"1985","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.bmc.2023.117558_b0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0223-5234(92)90005-L","article-title":"Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase","volume":"27","author":"Artico","year":"1992","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0140","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2174\/092986708785133022","article-title":"Semicarbazide-sensitive amine oxidase\/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target","volume":"15","author":"Dunkel","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0145","unstructured":"Matsukawa T., Masuzaki K., Yamamoto N., et al. Thiazole derivative and use thereof as VAP-1 inhibitor. WO2008066145. 2008."},{"key":"10.1016\/j.bmc.2023.117558_b0150","article-title":"Benzene or thiophene derivative and use thereof as VAP-1 inhibitor","author":"Matsukawa","year":"2009","journal-title":"WO2009145360"},{"key":"10.1016\/j.bmc.2023.117558_b0155","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1517\/13543776.2011.594040","article-title":"Semicarbazide-sensitive amine oxidase\/vascular adhesion protein-1: a patent survey","volume":"21","author":"Dunkel","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2023.117558_b0160","article-title":"Substituted 3-haloallylamine inhibitors of SSAO and uses thereof","author":"Deodhar","year":"2013","journal-title":"WO2013163675"},{"key":"10.1016\/j.bmc.2023.117558_b0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.113.207613","article-title":"PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO\/VAP-1 with anti-inflammatory effects in vivo","volume":"347","author":"Foot","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2023.117558_b0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bmc.2016.10.025","article-title":"Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors","volume":"25","author":"Yamaki","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0175","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/j.bmc.2017.05.059","article-title":"Synthesis and pharmacological evaluation of glycine amide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition","volume":"25","author":"Yamaki","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0180","article-title":"Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same","author":"Dong","year":"2019","journal-title":"WO2019180644"},{"key":"10.1016\/j.bmc.2023.117558_b0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12931-015-0200-z","article-title":"Effects of an anti-inflammatory VAP-1\/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration","volume":"16","author":"Schilter","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.bmc.2023.117558_b0190","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2023.117558_b0195","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/molecules25061293","article-title":"Human copper-containing amine oxidases in drug design and development","volume":"25","author":"Vakal","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2023.117558_b0200","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-8587(18)30289-4","article-title":"Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial","volume":"6","author":"de Zeeuw","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bmc.2023.117558_b0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40942-019-0178-7","article-title":"VIDI Research Group, Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema","volume":"5","author":"Nguyen","year":"2019","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.bmc.2023.117558_b0210","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1007\/s00216-016-9572-2","article-title":"HPLC-UV method for evaluation of inhibitors of plasma amine oxidase using derivatization of an aliphatic aldehyde product with TRIS","volume":"408","author":"Mergemeier","year":"2016","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0215","doi-asserted-by":"crossref","first-page":"e2200111","DOI":"10.1002\/ardp.202200111","article-title":"\u03c9-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted hydrazides and related compounds as inhibitors of amine oxidase copper containing 3 (AOC3)","volume":"355","author":"Galster","year":"2022","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2023.117558_b0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ab.2018.03.007","article-title":"HPLC-UV assays for evaluation of inhibitors of mono and diamine oxidases using novel phenyltetrazolylalkanamine substrates","volume":"549","author":"Mergemeier","year":"2018","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmc.2023.117558_b0225","doi-asserted-by":"crossref","first-page":"8355","DOI":"10.1039\/C6DT01212D","article-title":"Induced europium CPL for the selective signaling of phosphorylated amino acids and O-phosphorylated hexapeptides","volume":"45","author":"Neil","year":"2016","journal-title":"Dalton Trans"},{"key":"10.1016\/j.bmc.2023.117558_b0230","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00702-007-0684-x","article-title":"The origin of mammalian plasma amine oxidases","volume":"114","author":"Schwelberger","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmc.2023.117558_b0235","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s00011-005-0041-1","article-title":"Origins of plasma amine oxidases in different mammalian species","volume":"55","author":"Schwelberger","year":"2006","journal-title":"Inflamm Res"},{"key":"10.1016\/j.bmc.2023.117558_b0240","doi-asserted-by":"crossref","first-page":"9874","DOI":"10.1021\/acs.jmedchem.9b01283","article-title":"Identification and optimization of mechanism-based fluoroallylamine inhibitors of lysyl oxidase-like 2\/3","volume":"62","author":"Findlay","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0245","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.bmcl.2012.04.111","article-title":"The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase\/vascular adhesion protein-1 (SSAO\/VAP-1)","volume":"22","author":"Foot","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117558_b0250","doi-asserted-by":"crossref","first-page":"9042","DOI":"10.1021\/ac801429w","article-title":"Development of a selective ESI-MS derivatization reagent: synthesis and optimization for the analysis of aldehydes in biological mixtures","volume":"80","author":"Eggink","year":"2008","journal-title":"Anal Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0255","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00216-010-3575-1","article-title":"Targeted LC-MS derivatization for aldehydes and carboxylic acids with a new derivatization agent 4-APEBA","volume":"397","author":"Eggink","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0260","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1039\/C5AN00657K","article-title":"Profiling of aldehyde-containing compounds by stable isotope labelling-assisted mass spectrometry analysis","volume":"140","author":"Yu","year":"2015","journal-title":"Analyst"},{"key":"10.1016\/j.bmc.2023.117558_b0265","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/14756366.2018.1524890","article-title":"HPLC-UV assay for the evaluation of inhibitors of plasma amine oxidase using crude bovine plasma","volume":"34","author":"Mergemeier","year":"2019","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2023.117558_b0270","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00508-013-0354-y","article-title":"Serum diamine oxidase activity as a diagnostic test for histamine intolerance","volume":"125","author":"Mu\u0161i\u010d","year":"2013","journal-title":"Wien. Klein. Wochenschr."},{"key":"10.1016\/j.bmc.2023.117558_b0275","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/catal13010048","article-title":"Advances in the clinical application of histamine and diamine oxidase (DAO) activity: A review","volume":"13","author":"Tan","year":"2023","journal-title":"Catalysts"},{"key":"10.1016\/j.bmc.2023.117558_b0280","series-title":"Probit Analysis: A Statistical treatment of the sigmoid response curve","author":"Finney","year":"1952"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623004066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623004066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:24:26Z","timestamp":1760837066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623004066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":56,"alternative-id":["S0968089623004066"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117558","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03c9-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted glycine amides and related compounds as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117558"}}